

Hee-Jeong Cho

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1581392/publications.pdf>

Version: 2024-02-01

20
papers

149
citations

1478505

6
h-index

1199594

12
g-index

20
all docs

20
docs citations

20
times ranked

270
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 transmission and blood transfusion: A case report. <i>Journal of Infection and Public Health</i> , 2020, 13, 1678-1679.	4.1	77
2	Patients presenting high fever with lymphadenopathy after COVID-19 vaccination were diagnosed with hemophagocytic lymphohistiocytosis. <i>Infectious Diseases</i> , 2022, 54, 303-307.	2.8	16
3	Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and 18F-FDG PET/CT. <i>Blood Cancer Journal</i> , 2021, 11, 190.	6.2	10
4	Apparent diffusion coefficient as a valuable quantitative parameter for predicting clinical outcomes in patients with newly diagnosed primary CNS lymphoma. <i>Blood Research</i> , 2020, 55, 99-106.	1.3	9
5	Prognostic Significance of Clinicopathological and Molecular Features After Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients. <i>In Vivo</i> , 2019, 33, 1959-1965.	1.3	8
6	Therapeutic strategies, including allogeneic stem cell transplantation, to overcome relapsed/refractory adult T-cell acute lymphoblastic leukemia. <i>Expert Review of Hematology</i> , 2021, 14, 765-775.	2.2	8
7	Elevated Neutrophil-to-Lymphocyte Ratio Predicts Survival in Patients with Advanced Gastric Cancer Treated with Trastuzumab Combination Chemotherapy. <i>Anticancer Research</i> , 2018, 38, 3151-3156.	1.1	7
8	Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions. <i>Expert Review of Hematology</i> , 2021, 14, 819-830.	2.2	4
9	Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen. <i>Yeungnam University Journal of Medicine</i> , 2018, 35, 76-83.	1.4	3
10	Quantitative Assessment of Interim PET/CT Could Have More Prognostic Relevance than Visual Assessment for Predicting Clinical Outcome of Extranodal Diffuse Large B Cell Lymphoma. <i>In Vivo</i> , 2020, 34, 2127-2134.	1.3	3
11	Hypomethylating agent-based post-transplant strategies to maximize the outcome of high-risk acute myeloid leukemia after allogeneic stem cell transplantation. <i>Expert Review of Hematology</i> , 2020, 13, 959-969.	2.2	1
12	Clinical impact of cell-free serum Epstein-Barr virus status in patients with newly diagnosed malignant lymphoma. <i>Blood Research</i> , 2021, 56, 65-71.	1.3	1
13	Favorable Long-Term Outcomes with Autologous Stem Cell Transplantation for High-Risk Multiple Myeloma Patients with a Positive Result On 18F-FDG PET/CT at Baseline. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.4	1
14	Clinical impact of spine magnetic resonance imaging as a valuable prognostic tool for patients with multiple myeloma: a retrospective study. , 2022, 39, 300-308.		1
15	Favorable long-term survival using consolidation chemotherapy without allogeneic hematopoietic cell transplantation for acute myeloid leukemia with wild-type <i>NPM1</i> without <i>FLT3-ITD</i> . <i>Blood Research</i> , 2019, 54, 189-197.	1.3	0
16	Prognostic impact of 18F-FDG PET/CT in patients with multiple myeloma presenting with renal impairment. <i>International Journal of Hematology</i> , 2021, 113, 668-674.	1.6	0
17	High Residual Allelic Burden Increases Leukemic Transformation Irrespective of Clinical Response in Patients with Lower Risk Myelodysplastic Syndrome Treated with Azacitidine. <i>Blood</i> , 2019, 134, 4263-4263.	1.4	0
18	Clinical Impact of 18f-FDG PET/CT As a Valuable Prognostic Tool for the Newly Diagnosed Multiple Myeloma with Extramedullary Disease. <i>Blood</i> , 2019, 134, 3142-3142.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Development of a New Risk Stratification System for Patients with Newly Diagnosed Multiple Myeloma Using R-ISS and 18F-FDG PET/CT. <i>Blood</i> , 2021, 138, 3757-3757.	1.4	0
20	Light and shade of ruxolitinib: positive role of early treatment with ruxolitinib and ruxolitinib withdrawal syndrome in patients with myelofibrosis. <i>Expert Review of Hematology</i> , 0, , 1-9.	2.2	0